Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study

Background: Little is known about the clinical features of breast cancer with synchronous hepatic metastases (BCSHM). In this retrospective study, we aimed to feature the incidence and survival outcome of BCSHM.Methods: Data from the 2016 SEER*Stat database (version 8.3.2) was used. The effect of patient and tumor characteristics on the odds of developing of BCSHM was analyzed. Survival was investigated using Kaplan-Meier and Cox regression analyses. A competing risk model was also applied to further investigate cancer-specific survival.Results: Of 240911 patients with breast cancer, we identified 3468 patients (1.44%) with BCSHM. Tumor subtypes distribution of BCSHM were 45.3% HR+/HER2-, 12.2% HR+/HER2+, 7.83% HR-/HER2+ and 15.0% triple-negative subtype. The median OS of the entire cohort was 14 months, and only about 13.5% of patients survived at 3 years. Median survival was significantly shorter in triple-negative cohort (8 months) and gradually increased in HR+/HER2- (19 months), HR-/HER2+ (22 months) and HR+/HER2+ (33 months) cohorts (P
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

Authors: Xu Z, Xu P, Fan W, Huang B, Cheng Q, Zhang Z, Wang P, Yu M Abstract Fluorescent in situ hybridization (FISH) is commonly used to determine the ratio of human epidermal growth factor receptor 2 (HER2) to centromere enumeration probe for chromosome 17 (CEP17), which further determines HER2 gene status in breast cancer. However, due to copy number alteration in CEP17, inaccurate diagnoses can occur. The current study was performed to investigate the diagnostic value of an alternative CEP17 reference probe for HER2 status in invasive breast cancer. A higher-order repeat in the centromeric region of chromosome ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
AbstractPurpose of ReviewBreast cancer is now recognized to be a very heterogeneous disease. This complexity was recently reflected in the newest American Joint Committee on Cancer (AJCC) breast cancer staging, implemented in 2018. Although it seems very daunting, the new staging is based on both the anatomical extent of the disease and the prognostic factors such as hormonal and HER2 status, grade of the tumor, and genomic assays providing information regarding risk of recurrence. The purpose of this review is to illustrate the reasoning for the change in previous, solely an anatomically based breast cancer staging system...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
A new analysis looked at how dose interruptions or reductions of  ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conclusions: Collagen degradation markers are associated with response to neoadjuvant therapy and seem to play a role in breast cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and recur. The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were present or if tumor expressed PD-L1. We assessed whether type I polarized dendritic cells (DC1) could improve checkpoint therapy in a preclinical model of HER2+ breast cancer. TUBO bearing mice were vaccinated with either MHC class I or class II HER2 peptide pulsed DC1 (class I or class II HER2-DC1) concurrent or sequentially with administration of anti-PD-1 or anti-PDL1. Infiltration of tumors by immu...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion.With a longer follow‐up of almost 5 years, combination of weekly paclitaxel, trastuzumab, and pertuzumab remains effective with a favorable median PFS and a median OS not reached.Implications for Practice.The combination of weekly paclitaxel, trastuzumab, and pertuzumab has been endorsed by the National Comprehensive Cancer Network as one of the first‐line treatment options in patients with human epidermal growth receptor 2 (HER2)‐positive metastatic breast cancer (MBC). However, the long‐term safety and efficacy are still unknown. Findings from this phase II study provide favorable preliminary data on t...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Conclusions: Our results provide evidence for the H19-mediated regulation of trastuzumab resistance in HER2-positive breast cancer cells. H19 could act as a potential predictive biomarker for HER2-positive breast cancer patients, and downregulation of H19 could reverse trastuzumab resistance and enhance the inhibitory function of this drug.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
In this report, we discuss the prognostic impact of these parameters and the necessity of their correct assessment in the diagnostic routine.
Source: Virchows Archiv - Category: Pathology Source Type: research
Conditions:   Bilateral Breast Carcinoma;   Breast Carcinoma;   HER2/Neu Negative;   Mastectomy Patient;   Recurrent Breast Carcinoma;   Triple-Negative Breast Carcinoma Interventions:   Drug: ATR Kinase Inhibitor M6620;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer;   a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status Interventions:   Drug: Durvalumab;   Drug: Olaparib;   Drug: Fulvestrant Sponsors:   UNICANCER;   ARCAGY- GYNECO;   SOLTI Breast Cancer Research Group Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | HER2 | Study